Seizures Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2025-2034)

The seizures market was valued at USD 5.17 Billion in 2024, driven by the increasing prevalence of seizure disorders across the 8 major markets. The market is expected to grow at a CAGR of 4.42 % during the forecast period of 2025-2034, with the values likely to reach USD 7.97 Billion by 2034 .

Seizures Market Overview

A seizure is characterized by a sudden and uncontrolled burst of electrical activity in the brain, causing the change in movements, levels of consciousness, behavior, and feelings. They typically last from 30 seconds to 2 minutes. The types of seizures vary depending on where they originate in the brain and how far they spread. The rising incidence of epilepsy and other seizure disorders is a primary driver of the market, propelling the demand for effective treatments. The market benefits from the increased research and innovation in the field of neurology and the rising introduction of targeted therapies and biologics. Additionally, advancements in diagnostic technologies, rising healthcare expenditure, and the growing demand for precision medicine are anticipated to impact the market dynamics.

Seizures Market Growth Drivers

Increasing Prevalence of Seizure Disorders is Driving Market Growth

According to the World Health Organisation (WHO), epilepsy ranks as one of the most common neurological diseases and affects about 50 million individuals globally. It is estimated that nearly 50 million individuals suffering from epilepsy are living in low- and middle-income countries, reflecting the need for affordable and effective anti-epileptics. Moreover, recent data suggests that around 10% of individuals have one seizure in their lifetime. The increasing number of cases of epilepsy and other seizure disorders is expected to drive market growth in the coming years.

Seizures Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Drug Approvals to Affect the Market Landscape Significantly

In April 2024, the subsidiary of South Korean biotech company SK Biopharmaceuticals, SK Life Science announced the regulatory approval from the United States Food and Drug Administration (FDA) for two new administration options for its antiseizure medication XCOPRI (cenobamate tablets) CV indicated for partial-onset (focal) seizures in adults. The drug can be crushed and mixed with water, allowing it to be administered either as an oral suspension via mouth or through a nasogastric tube. The rise in such approvals from the regulatory agencies is poised to support the market growth in the forecast period.

Increased Availability of Generic Medications Poised to Augment Seizures Market Demand

In March 2024, Indian multinational pharmaceutical company Lupin Limited announced that its Abbreviated New Drug Application (ANDA) for Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, received approval from the United States Food and Drug Administration (U.S. FDA). The Eslicarbazepine Acetate Tablets are a generic version of Aptiom® Tablets developed by Sumitomo Pharma America, Inc., and are indicated for patients affected by partial-onset seizures who are 4 years and older. The rising entry of generic antiepileptic drugs are likely to boost market demand in the coming years.

Growing Focus on Non-Pharmacological Interventions to Elevate the Seizures Market Value

A major market trend is the growing focus on non-drug treatments, such as vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation, to improve the treatment efficiency for drug-resistant epilepsy. These neurostimulation devices can help to reduce the frequency and intensity of seizures, thereby offering alternative therapies to patients suffering from epilepsy.

Use of Cannabinoid-Based Therapies to Boost Seizures Market Size

One of the significant market trends is the increased use of cannabinoid-based treatments, such as cannabidiol (CBD), for the treatment of hard-to-treat epileptic conditions like Dravet syndrome and Lennox-Gastaut syndrome. Further, the rise in research activities directed at finding potential applications for cannabinoids in seizure management is poised to augment the market size in the forecast period.

Seizures Market Segmentation

Seizures Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type

• First Generation Anti-Epileptics
• Second Generation Anti-Epileptics
• Third Generation Anti-Epileptics

Market Breakup by Route of Administration

• Oral
• Parenteral
• Topical

Market Breakup by End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Others

Market Breakup by Distribution Channel

• Hospitals Pharmacies
• Independent Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• India
• Japan

Seizures Market Share

The Drug Type Segment Represents a Significant Market Share

The market segmentation by drug type includes first-generation, second-generation, and third-generation anti-epileptic drugs. The first-generation anti-epileptics segment comprises initial treatments that were developed for the treatment of seizures and epilepsy. These drugs such as Phenobarbital and Carbamazepine (Tegretol) are generally less expensive and widely prescribed in low- and middle-income regions. On the other hand, third-generation anti-epileptics include the newest class of seizure treatment that has reduced side effects, improved efficacy, and less frequent dosing.

Seizures Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds the largest market share owing to the high diagnosis rates of seizure disorders and the easy availability of second- and third-generation anti-epileptic drugs. The growing demand for novel therapies such as immunotherapy and precision medicine also supports the market growth in the region. Moreover, the robust investment in research and development to advance seizure treatments and the presence of a favorable regulatory environment are poised to fuel market expansion in the region.

Leading Players in the Seizures Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Pfizer Inc

Pfizer is one of the leading players in the market that focuses on the development of novel therapies for seizures and neurological disorders. Pfizer’s Celontin® (Methsuximide Capsules, USP) is indicated for the treatment of absence (petit mal) seizures and works by suppressing the wave activity linked with lapses of consciousness.

UCB S.A.

Multinational biopharmaceutical company UCB S.A., based in Brussels, Belgium, is focused on research and development, specializing primarily in the discovery of novel medications for epilepsy, Crohn's disease, and Parkinson's disease. One of the company’s key products is BRIVIACT® (brivaracetam) which is prescribed as adjunctive therapy used to treat partial-onset seizures with or without secondary generalization in patients with epilepsy.

Sanofi

Sanofi, headquartered in Paris, France, has a prominent presence in the market and provides a wide range of medications for neurological disorders, including epilepsy and seizures. Sanofi’s Depakine (sodium valproate), a broad-spectrum anti-epileptic drug, is a reference treatment for epilepsy globally.

Novartis AG

Swiss multinational pharmaceutical company Novartis AG plays a significant role in the growth of the market. Its popular drug Afinitor DISPERZ (everolimus) is an FDA-approved adjunctive treatment for tuberous sclerosis complex (TSC)-associated partial-onset seizures patients aged 2 years and above.

Other key players in the market include GSK plc, Eisai Co. Ltd, Abbott, Sumitomo Pharmaceutical Co. Ltd, Teva Pharmaceutical Ltd, and Takeda Pharmaceutical Company Limited.

Key Questions Answered in the Seizures Market Report

• What was the seizures market value in 2024?
• What is the seizures market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on drug type?
• What is the market breakup based on the route of administration?
• Who are the major end users in the market?
• What is the market breakup by distribution channel?
• What are the major factors aiding the seizures market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do the prevalence and incidence of seizure disorders affect the market landscape?
• What are the major seizures market trends?
• How does the rise in the geriatric population impact the market size?
• Which drug type will dominate the market share?
• Which route of administration is expected to have a high market value in the coming years?
• Which distribution channel will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the seizures market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

More Insights On:

Tonic-Clonic Seizures Treatment Market

Seizures Drug Pipeline Analysis

This product will be delivered within 3-5 business days.